Real-world drug utilization patterns in patients initiating Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) for treating T2DM in Italy

Trial Profile

Real-world drug utilization patterns in patients initiating Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) for treating T2DM in Italy

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Dulaglutide (Primary) ; Exenatide (Primary) ; Liraglutide (Primary) ; Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Apr 2018 New trial record
    • 01 Apr 2018 Results published in the Diabetes Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top